The Obstructive Sleep Apnea Mortality Paradox: Why a High-Risk Disorder Can Appear Protective in Short-Term Outcome Studies

Obstructive sleep apnea (OSA) is a common disorder associated with hypertension, coronary disease, stroke, and increased long-term mortality. Despite this, a growing body of observational studies, particularly analyses of administrative databases and intensive care cohorts, has reported lower short-term or in-hospital mortality among patients diagnosed with OSA. This unexpected finding has been termed the “OSA mortality paradox.” This narrative review synthesizes the evidence supporting this paradox, contrasts it with the well-established long-term risks of untreated OSA, and evaluates competing explanations for its occurrence. Potential biological mechanisms include intermittent hypoxia-induced preconditioning, obesity-related metabolic reserve, and adaptation of the right ventricle or autonomic system to recurrent physiological stress.However, the most compelling explanations are methodological. These include detection bias, under-recognition of OSA in comparison groups, residual confounding by obesity and healthcare access, and the inability of many datasets to capture disease severity, hypoxic burden, frailty, and adherence to positive airway pressure therapy. A key distinction in interpreting this paradox lies between physiological OSA and diagnosed OSA. While physiological OSA is plausibly harmful, diagnosed OSA may identify patients who are already engaged with healthcare, screened for comorbidities, and more likely to receive cardiopulmonary monitoring or treatment. We contend that current evidence does not support a genuinely protective effect of OSA itself. Instead, the paradox is best understood as a context-specific epidemiological artifact superimposed on a biologically heterogeneous disease. Future research should integrate polysomnographic severity, hypoxic burden, treatment exposure, and modern causal inference methods to ensure that short-term outcome studies do not confuse diagnostic labeling with true pathophysiological benefit.